Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Non Small Cell Lung Cancer · Nonsquamous Non Small Cell Lung Cancer · Squamous Non Small Cell Lung Cancer · Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jul 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 2
- Patients
- 151 (final count)
- Started
- May 28, 2020
- Main results expected
- Jul 9, 2025
- Fully finished
- Jul 9, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Progression-free survival (PFS)
Measured over: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-07-09, no fading
Raw record changes
- none yet
Trial ID NCT04262856 · record last updated 2026-06-15 · checked 2026-11-09 15:47 UTC